A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 83, Issue 2, 2013, Pages 285-292

  Chan, John Gar Yan ^a   Chan, Hak Kim ^a   Prestidge, Clive A ^b   Denman, John A ^b   Young, Paul M ^a   Traini, Daniela ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Aerosol; Antibiotics; Dry powder; Inhalation; Spray drying; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; AEROSOL; EXCIPIENT; POWDER; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; DRY POWDER; IN VITRO STUDY; INHALATION; PHYSICAL CHEMISTRY; QUANTITATIVE ANALYSIS; SPRAY DRYING; AEROSOL; CHEMISTRY; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PARTICLE SIZE; POWDER; PROCEDURES;

ADMINISTRATION, INHALATION; AEROSOLS; ANTIBIOTICS, ANTITUBERCULAR; CHEMISTRY, PHARMACEUTICAL; DRY POWDER INHALERS; EXCIPIENTS; PARTICLE SIZE; POWDERS;

EID: 84873703779     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.08.007     Document Type: Article

References (38)

1. W. World Health Organisation, Standard Treatment Regimens, in: Treatment of Tuberculosis: Guidelines, fourth ed., WHO Press, Geneva, 2010, pp. 29-42.
2. C. Lienhardt, S.V. Cook, M. Burgos, V. Yorke-Edwards, L. Rigouts, G. Anyo, S.J. Kim, A. Jindani, D.A. Enarson, and A.J. Nunn Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial JAMA 305 2011 1415 1423
3. C.D. Mitnick, B. McGee, and C.A. Peloquin Tuberculosis pharmacotherapy: strategies to optimize patient care Expert Opin. Pharmacother. 10 2009 381 401
4. R. Pandey, and G.K. Khuller Antitubercular inhaled therapy: opportunities, progress and challenges J. Antimicrob. Chemother. 55 2005 430 435
5. Y. Xie, P. Zeng, and T.S. Wiedmann Disease guided optimization of the respiratory delivery of microparticulate formulations Expert Opin. Drug Deliv. 5 2008 269 289
6. M. Gonzalez-Juarrero, and M.P. O'Sullivan Optimization of inhaled therapies for tuberculosis: the role of macrophages and dendritic cells Tuberculosis (Edinb) 91 2011 86 92
7. I. Coowanitwong, V. Arya, P. Kulvanich, and G. Hochhaus Slow release formulations of inhaled rifampin AAPS J. 10 2008 342 348
8. A. Misra, A.J. Hickey, C. Rossi, G. Borchard, H. Terada, K. Makino, P.B. Fourie, and P. Colombo Inhaled drug therapy for treatment of tuberculosis Tuberculosis (Edinb) 91 2011 71 81
9. T. Mizoe, T. Ozeki, and H. Okada Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles AAPS PharmSciTech 9 2008 755 761
10. P. Muttil, J. Kaur, K. Kumar, A.B. Yadav, R. Sharma, and A. Misra Inhalable microparticles containing large payload of anti-tuberculosis drugs Eur. J. Pharm. Sci. 32 2007 140 150
11. R. Pandey, A. Sharma, A. Zahoor, S. Sharma, G.K. Khuller, and B. Prasad Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 2003 981 986
12. R. Sharma, D. Saxena, A.K. Dwivedi, and A. Misra Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis Pharm. Res. 18 2001 1405 1410
13. Y.J. Son, and J.T. McConville A new respirable form of rifampicin Eur. J. Pharm. Biopharm. 78 2011 366 376
14. R.K. Verma, A.K. Singh, M. Mohan, A.K. Agrawal, and A. Misra Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulates drug-delivery systems Therapeut. Deliv. 2 2011 753 768
15. A.B. Yadav, R. Sharma, P. Muttil, A.K. Singh, R.K. Verma, M. Mohan, S.K. Patel, and A. Misra Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy Indian J. Exp. Biol. 47 2009 469 474
16. A. Sosnik, A.M. Carcaboso, R.J. Glisoni, M.A. Moretton, and D.A. Chiappetta New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery Adv. Drug Deliv. Rev. 62 2010 547 559
17. P. Blasi, A. Schoubben, S. Giovagnoli, C. Rossi, and M. Ricci Fighting tuberculosis: old drugs, new formulations Expert Opin. Drug Deliv. 6 2009 977 993
18. P. Muttil, C. Wang, and A.J. Hickey Inhaled drug delivery for tuberculosis therapy Pharm. Res. 26 2009 2401 2416
19. R. Sharma, P. Muttil, A.B. Yadav, S.K. Rath, V.K. Bajpai, U. Mani, and A. Misra Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra J. Antimicrob. Chemother. 59 2007 499 506
20. N.Y. Chew, and H.K. Chan In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler J. Aerosol Med.: Off. J. Int. Soc. Aerosols Med. 14 2001 495 501
21. E. Calleri, E. De Lorenzi, S. Furlanetto, G. Massolini, and G. Caccialanza Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation J. Pharm. Biomed. Anal. 29 2002 1089 1096
22. R.O. Salama, D. Traini, H.-K. Chan, and P.M. Young Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: Evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols Eur. J. Pharm. Biopharm. 70 2008 145 152
23. P. Duport, R. Robertson, K. Ho, and F. Horvath Flow-through dissolution of uranium-thorium ore dust, uranium concentrate, uranium dioxide, and thorium alloy in simulated lung fluid radiation protection Dosimetry 38 1991 121 133
24. R. Kumar Verma, J.K. Mukker, R.S. Singh, K. Kumar, P.R. Verma, and A. Misra Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques Mol. Pharm. 9 2012 1011 1016
25. Y.-J. Son, and J.T. McConville Preparation of sustained release rifampicin microparticles for inhalation J. Pharm. Pharmacol. 2012 no-no
26. S. Suarez, P. O'Hara, M. Kazantseva, C.E. Newcomer, R. Hopfer, D.N. McMurray, and A.J. Hickey Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model Pharm. Res. 18 2001 1315 1319
27. R.K. Verma, J. Kaur, K. Kumar, A.B. Yadav, and A. Misra Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice Antimicrob. Agents Chemother. 52 2008 3195 3201
28. J. Fiegel, L. Garcia-Contreras, M. Thomas, J. VerBerkmoes, K. Elbert, A. Hickey, and D. Edwards Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin Pharm. Res. 25 2008 805 811
29. L. Garcia-Contreras, J. Fiegel, M.J. Telko, K. Elbert, A. Hawi, M. Thomas, J. VerBerkmoes, W.A. Germishuizen, P.B. Fourie, A.J. Hickey, and D. Edwards Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model Antimicrob. Agents Chemother. 51 2007 2830 2836
30. J.C. Sung, L. Garcia-Contreras, J.L. Verberkmoes, C.A. Peloquin, K.J. Elbert, A.J. Hickey, and D.A. Edwards Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation Antimicrob. Agents Chemother. 53 2009 1338 1343
31. N. Tsapis, D. Bennett, K. O'Driscoll, K. Shea, M.M. Lipp, K. Fu, R.W. Clarke, D. Deaver, D. Yamins, J. Wright, C.A. Peloquin, D.A. Weitz, and D.A. Edwards Direct lung delivery of para-aminosalicylic acid by aerosol particles Tuberculosis (Edinb) 83 2003 379 385
32. S. Adi, H. Adi, H.K. Chan, Z. Tong, R. Yang, A. Yu, Effects of mechanical impaction on aerosol performance of particles with different surface roughness, Powder Technol., in press (corrected proof).
33. T. Hasegawa, K. Hirota, K. Tomoda, F. Ito, H. Inagawa, C. Kochi, G. Soma, K. Makino, and H. Terada Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres and PLGA microspheres loaded with anti-tuberculosis agent Colloids Surf. B Biointerf. 60 2007 221 228
34. S. Ahmad, B.F. Johnston, S.P. Mackay, A.G. Schatzlein, P. Gellert, D. Sengupta, and I.F. Uchegbu In silico modelling of drug-polymer interactions for pharmaceutical formulations J. Roy. Soc. Interf. 7 suppl. 4 2010 S423 S433
35. M. Dolezal, J. Zitko, Z. Osicka, J. Kunes, M. Vejsova, V. Buchta, J. Dohnal, J. Jampilek, and K. Kralova Synthesis, antimycobacterial, antifungal and photosynthesis-inhibiting activity of chlorinated N-phenylpyrazine-2- carboxamides Molecules 15 2010 8567 8581
36. I.P. Kaur, and R.K. Verma Exploring solid lipid nanoparticles for intranasal administration of streptomycin Int. J. Pharm. 1 2011 110 117
37. R.A.E. Castro, T.M.R. Maria, A.n.O.L. Évora, J.C. Feiteira, M.R. Silva, A.M. Beja, J.O. Canotilho, and M.E.S. Eusébio A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships Cryst. Growth Des. 10 2009 274 282
38. N. Wheate, V. Vora, N. Anthony, and F. McInnes Host-guest complexes of the antituberculosis drugs pyrazinamide and isoniazid with cucurbit[7]uril J. Incl. Phenom. Macrocyc. Chem. 68 2010 359 367